General description
A fixed-dose combination regimen of the direct acting antiviral agents sofosbuvir and velpatasvir for the treatment of genotypes 1-6 chronic hepatitis C virus (HCV) infection.
INN
Sofosbuvir + velpatasvir
ATC codes
Medicine type
Chemical agent
EML status history
First added in 2017
(TRS
1006)
for
Chronic hepatitis C
Wikipedia
DrugBank
Recommendations
Section
Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations
- Oral > Solid > tablet: 200 mg + 50 mg; 400 mg + 100 mg
Indications